Tezepelumab Study for Adults With Moderate to Very Severe COPD
Tests tezepelumab against placebo in adults with moderate to very severe COPD.
Plain-language title generated from the registry record
Registry title: A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
Key facts
- Where
- Bucharest, Cluj-Napoca, Oradea, Timisoara, and Timișoara, RomaniaSee the 8 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 80 years old?
Source: NCT06878261, who can take part
Where in Romania
- Clinica Pajura SRLBucharest, RomaniaTaking people
- Spitalul de Urgenta al Ministerului Administratiei si Internelor "Prof. Dr. Dimitrie Gerota"Bucharest, RomaniaTaking people
- Cabinet Medical de Pneumologie Dr Mincu BogdanCluj-Napoca, RomaniaTaking people
- Spitalul Clinic de Pneumoftiziologie Leon DanielloCluj-Napoca, RomaniaTaking people
- Spitalul Clinic Judetean De Urgenta BihorOradea, RomaniaTaking people
- Neoclinic Concept S.R.L.Timisoara, RomaniaTaking people
- Clinical Hospital of Infectious Diseases and Pneumophysiology Dr.Victor Babeș TimișoaraTimișoara, RomaniaTaking people
- Fundatia CardiopreventTimișoara, RomaniaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06878261EU 2024-517457-27-00
- Record updated
- 9 October 2026
- Original description
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)Read full original descriptionShow less
A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Inclusion: ≥40 to ≤80 years old; COPD diagnosis ≥1 year,; Post-BD FEV1 ≥ 20% and ≤ 70% PN, FEV1/FVC <0.70 at screening; Triple (ICS+LABA+LAMA) or dual inhaled COPD therapy, if triple therapy is considered not appropriate, ≥3 consecutive months prior to V1; ≥2 moderate or ≥1 severe COPD exacerbations in the prior year; At least 1 of 2 moderate exacerbations must require the use of systemic corticosteroids. At least one of the previous exacerbations should be confirmed to have occurred while the participant was on triple or dual inhaled maintenance therapy; EOS ≥ 150 cells/μL during screening; CAT ≥15 at screening; Former or current smokers ≥10 pack-years.
Exclusion: Tuberculosis requiring treatment within 12 months prior V2; Malignancies current or past; Concomitant therapies:; Macrolides (less than 6 months); Systemic immuno-suppressive, -modulating medications; Clin. important pulmonary disease or radiological findings suggestive of a respiratory disease other than COPD; Any unstable disorder that can impact participants safety or study outcomes; Asthma, incl. pediatric, or ACOS; LTOT >4.0 L/min or O2 saturation <89% despite LTOT.